AVAST Anomalies Vasculaires Associées au Syndrome de Turner (Vascular Abnormalities Associated With Turner Syndrome)
AVAST
Detect, Monitor and Prevent Vascular Abnormalities Associated With Turner Syndrome
1 other identifier
observational
125
1 country
6
Brief Summary
Turner syndrome is a genetic condition, rare, due to the total or partial absence of one X chromosome, affecting 1/2500 newborn female. It combines almost constantly short stature and ovarian failure with infertility. Other anomalies are inconstant: morphological characteristics of varying intensity, associated malformations, and increased risk of acquired diseases ... The prognosis of patients reaching the Turner Syndrome is linked to cardiovascular complications (congenital heart disease, dilatation of the ascending aorta with risk of dissection or rupture of aneurysm), causing early mortality with reduction of life expectancy of at least 10 years. For these reasons, screening for heart disease and dilatation of the ascending aorta is established and is intended to prevent the complications associated with medical treatment and / or surgery to increase life expectancy and reduce the co-morbidities. On the vascular level, the recommendations other than those relating to the monitoring of the diameter of the ascending aorta include research of renal artery stenosis by doppler ultrasound if the patient is hypertensive and looking for lymphedema. However, other arterial lesions were described in the literature, outside of the aneurysm of the ascending aorta. These peripheral arterial lesions can also be life and / or functional prognosis of the patient. Ascending aorta dilation seems not to be exclusive in Turner syndrome. In addition, specific vascular lesions outside the affected artery are described: hepatic cirrhosis by vascular depletion, lymphedema and varicose veins. The prevalence of venous or lymphatic disease is unknown. A single-center review of 9 cases of patients followed at the University Hospital of Strasbourg showed the presence of vascular lesions discovered incidentally during assessments performed for reasons other than cardiovascular screening: cystic lymphangioma, internal carotid aneurysm, agenesis of the inferior vena cava, early varicose veins, embryonic cerebral artery, etc ... None of these patients showed any dilatation of the ascending aorta or heart disease. Peripheral vascular abnormalities in this patient group are exclusive. In this study, we seek to demonstrate that arterial disease in Turner syndrome involve the entire arterial territory and is not confined to the ascending aorta. Screening for arterial lesions should be performed on the entire arterial vascular tree and regularly in the course of time, especially as the presence of cardiovascular risk factors increases with the age of these patients. The venous and lymphatic vascular damage in the literature and in our series of cases in University Hospital of Strasbourg description should also lead to the detection of these lesions. These vascular complications can be alone responsible for the reduction in life expectancy or responsible for serious morbidity. Improved screening of associated vascular lesions is necessary to enable the best prevention of cardiovascular complications. It is also to establish the prevalence of vascular anomalies, whether arterial, venous or lymphatic, to better understand the disease and its management. By collecting systematically karyotype leading to diagnosis, it may be possible to make a link between the genetic defect and heart or vascular disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2013
Longer than P75 for all trials
6 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2013
CompletedFirst Submitted
Initial submission to the registry
September 23, 2014
CompletedFirst Posted
Study publicly available on registry
September 26, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2024
CompletedJune 30, 2022
June 1, 2022
11 years
September 23, 2014
June 28, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Collection of clinical events and systematized vascular ultrasound explorations
Reports of annual clinical events and results of complementary cardiovascular investigations. Systematized arterial and venous ultrasound explorations once a year. Reports karyotype used to put the diagnosis of turner Syndrome to perform correlations karyotype - phenotype and karyotype - event. Annual standardized biological exploration.
Annual evaluation with a 5 years follow-up
Study Arms (1)
Turner syndrome patients and vascular abnormalities
Interventions
vascular ultrasound explorations
Eligibility Criteria
All patient with Turner Syndrome.
You may qualify if:
- Any woman over 18 years with Turner Syndrome confirmed by karyotype
- Affiliated to a social security scheme
- Having signed an informed consent
- Having been informed of the results of the medical examination prior
You may not qualify if:
- Inability to give informed patient information related to comprehension difficulties
- Topic featuring against-indications for MRI examination:
- pacemaker or automatic defibrillator, implanted pump
- auditory nerve stimulator, anal nerve stimulator, etc ...
- the ferromagnetic objects in the soft tissues, intraocular metallic objects, cerebral vascular clips
- claustrophobia
- morphotype not allowing access to MRI
- Patient under judicial protection, guardianship or trusteeship
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (6)
Service de Chirurgie et Médecine Vasculaire, CHU Jean Minjoz
Besançon, 25030, France
Service d'Angiologie, CHU Bocage
Dijon, 21079, France
Service de gynécologie, Centre Médico Chirurgical Obstétrical, Hôpitaux Universitaires
Schiltigheim, 67303, France
Service d'endocrinologie, Hôpital Civil, Hôpitaux Universitaires
Strasbourg, 67091, France
Service d'explorations fonctionnelles non invasives cardio-vasculaires, Nouvel Hôpital Civil, Hôpitaux Universitaires
Strasbourg, 67091, France
Service HTA, maladies vasculaires et pharmacologie clinique, Nouvel Hôpital Civil, Hôpitaux Universitaires
Strasbourg, 67091, France
Biospecimen
Blood
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sébastien GAERTNER, MD
Hôpitaux Universitaires de Strasbourg
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 23, 2014
First Posted
September 26, 2014
Study Start
July 1, 2013
Primary Completion
July 1, 2024
Study Completion
July 1, 2024
Last Updated
June 30, 2022
Record last verified: 2022-06